Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements
Status:
Not yet recruiting
Trial end date:
2024-09-29
Target enrollment:
Participant gender:
Summary
Osteoarticular infections associated with hip and knee prostheses require optimal surgical
and medical management to maximize the rate of therapeutic success. Antibiotic therapy should
be administered for a period of 12 weeks. Tolerance problems, difficulties in maintaining
compliance over 12 weeks, bacterial multidrug resistance and sometimes intravenous
administration are the main obstacles to appropriate antibiotic therapy and to limiting
iatrogenicity. Dalbavancin is an antibiotic derived from teicoplanin (glycopeptide) with a
long half-life, of punctual parenteral administration without a central line, active on
staphylococci, and well tolerated. The data in the literature concerning its efficacy in
Osteoarticular infections associated with hip and knee prostheses are limited and
heterogeneous. Investigators would like to describe its efficacy in a homogeneous series of
patients in terms of the type of infection, their surgical management and the methods of
administration of the product in order to extend its use.